Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion ...

This additional investment is part of the most ambitious manufacturing expansion agenda in the company's history. Since 2020, ...

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

While Cork is already successful in the production of industry winners, Eli Lilly's obesity and weight loss drugs are ...

The conventional wisdom is that there are two important aspects of timing in investing: when to buy a stock and when to sell ...

This brings Eli Lilly’s total investment to $9bn (€8.2bn), the largest in the company's 150-year history. Last week, the world's most valuable pharmaceutical firm announced plans to invest $1 ...

Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to ...

Eli Lilly is investing $1 billion to expand its Limerick, Ireland site for biologic active ingredients, including Alzheimer's treatment components. This adds to a $2 billion total investment in ...

TSMC is a Taiwan-based semiconductor manufacturing company that has a market capitalisation of $893.71B and an annual growth ...